323 related articles for article (PubMed ID: 27567160)
1. Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.
Bailey RA; Schwab P; Xu Y; Pasquale M; Renda A
Clin Ther; 2016 Sep; 38(9):2046-2057.e2. PubMed ID: 27567160
[TBL] [Abstract][Full Text] [Related]
2. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
[TBL] [Abstract][Full Text] [Related]
3. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
4. An observational study of glycemic control in canagliflozin treated patients.
Meckley LM; Miyasato G; Kokkotos F; Bumbaugh J; Bailey RA
Curr Med Res Opin; 2015 Aug; 31(8):1479-86. PubMed ID: 25986535
[TBL] [Abstract][Full Text] [Related]
5. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
6. HbA
Thayer S; Aguilar R; Korrer S; Chow W
Clin Ther; 2017 Oct; 39(10):2061-2072. PubMed ID: 28943114
[TBL] [Abstract][Full Text] [Related]
7. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
Buysman EK; Anderson A; Bacchus S; Ingham M
Adv Ther; 2017 Apr; 34(4):937-953. PubMed ID: 28251556
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
Buysman EK; Chow W; Henk HJ; Rupnow MF
Curr Med Res Opin; 2015 Jan; 31(1):137-43. PubMed ID: 25356602
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
[TBL] [Abstract][Full Text] [Related]
11. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.
Wilding JP; Blonde L; Leiter LA; Cerdas S; Tong C; Yee J; Meininger G
J Diabetes Complications; 2015 Apr; 29(3):438-44. PubMed ID: 25660137
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
Buysman EK; Chow W; Henk HJ; Rupnow MF
BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
[TBL] [Abstract][Full Text] [Related]
14. Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA
Johnson JF; Parsa R; Bailey RA
Clin Ther; 2017 Jun; 39(6):1123-1131. PubMed ID: 28495028
[TBL] [Abstract][Full Text] [Related]
15. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Lefebvre P; Pilon D; Robitaille MN; Lafeuille MH; Chow W; Pfeifer M; Duh MS
Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
[TBL] [Abstract][Full Text] [Related]
16. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.
McAdam-Marx C; Bellows BK; Unni S; Wygant G; Mukherjee J; Ye X; Brixner DI
J Manag Care Spec Pharm; 2014 Jul; 20(7):691-700. PubMed ID: 24967522
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Kutoh E; Wada A; Murayama T; Takizawa Y
Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448
[TBL] [Abstract][Full Text] [Related]
18. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
[TBL] [Abstract][Full Text] [Related]
19. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy.
Schwab P; Racsa P; Rascati K; Mourer M; Meah Y; Worley K
J Manag Care Spec Pharm; 2019 Mar; 25(3):332-340. PubMed ID: 30816817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
